Diffuse alveolar hemorrhage - review of an interstitial lung disease clinic
Conclusion: DAH is a severe disorder, with nonspecific presentation, caused by a wide spectrum of disease, as demonstrated by this series. Diagnosis requires high clinical suspicion and a thorough work-up.
Conclusion: The knowledge about hypertension among majority of patients was reasonable. But they were unaware of their disease status. The drug compliance among them was poor. Forgetfulness and interruptions of daily routine were common reasons attributed for nonadherence. PMID: 29230325 [PubMed]
Authors: Jankauskiene J, Jarusaitiene D Abstract Purpose: To investigate juvenile Graves' ophthalmopathy (GO) signs and compare Graves' disease (GD) course in patients with or without GO. Patients and Methods: There were analyzed data (visual acuity, proptosis, palpebral fissure measurements, clinical activity score (CAS), and the course of GD) of 67 children who have been newly diagnosed with GD. 26.9% of patients with GD had signs of ophthalmopathy (GO+), and 73.1% were without ophthalmopathy (GO-). Results: Upper eyelid retraction (72.3%), proptosis (66.7%), and soft tissue changes (27.8-38.9%) were in G...
Conclusion: Small dogs had a lower antioxidant status and differences in circulating amino acids. Some of the amino acid differences could be attributed to differences in microflora. Additionally, analysis of small dog metabolites and clinical parameters reflected a network which strongly associates with kidney function. PMID: 29225968 [PubMed]
The new ACC/AHA guidelines for hypertension lowered the threshold for a diagnosis of hypertension. Are these changes justified?Georgetown University Family Medicine
Conditions: Megaloblastic Anemia Nos; Pernicious Anemia Intervention: Drug: Hydroxocobalamin 10,000mcg, Thiamin 100mg, Pyridoxine 50mg Sponsor: Hospital Universitario Dr. Jose E. Gonzalez Recruiting
Conditions: Cardiovascular Diseases; Hypertension Interventions: Other: Normotensive; Drug: Hypertensives Sponsors: University of Delaware; National Institutes of Health (NIH) Not yet recruiting
Condition: Essential Hypertension Intervention: Drug: Valsartan, Amlodipine - Sponsor: PharmEvo Pvt Ltd Not yet recruiting
Condition: Systemic Lupus Erythematosus Interventions: Drug: BOS161721; Drug: Placebo Sponsor: Boston Pharmaceuticals Recruiting
Conditions: Hypertension, Pulmonary; Anemia, Iron Deficiency Intervention: Drug: Ferric maltol 30 mg (Feraccru®) Sponsors: Hannover Medical School; Shields, Shields and Associates Not yet recruiting
Conditions: Menopause; Elevated Blood Pressure; Hypertension; Endothelial Dysfunction Interventions: Dietary Supplement: Blueberry Powder; Dietary Supplement: Placebo Powder Sponsors: Colorado State University; U.S. Highbush Blueberry Council Recruiting